Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pacira Pharmaceuticals has announced the positive results of Exparel (bupivacaine liposome extended-release injectable suspension) in reducing opioid burdens as compared to compared to bupivacaine HCl.
Subscribe to our email newsletter
Exparel is a long-acting bupivacaine which combines product delivery technology, DepoFoam and is an anesthetic/analgesic.
The data has been pooled from five active-control, double-blind, randomized, multicenter, parallel-group trials comprising over 700 patients.
The study demonstrated that Exparel resulted in longer time to first opioid use (TTFO), a reduced overall consumption of opioids, fewer opioid-related adverse events (ORAEs) and better pain control compared to bupivacaine HCl.